|
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma Clinical research trials and Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma. Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma  Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
For Condition: adult anaplastic oligodendroglioma,adult glioblastoma multiforme,Mixed Gliomas,adult anaplastic astrocytoma,recurrent adult brain tumor
Status: Recruiting
Sponsor(s): North American Brain Tumor Consortium , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrentmalignantglioma.
Details: OBJECTIVES: - Determine the maximum tolerated dose and dose-limiting toxicity of irinotecan when administered with temozolomide in patients with recurrent malignant glioma. - Determine the safety profile of this regimen in this patient population. - Determine the efficacy of this treatment regimen as measured by 6-month progression-free survival and objective tumor response in these patients. - Characterize the pharmacokinetics of this treatment regimen in these patients. - Determine the antitumor activity of this treatment regimen in these patients. OUTLINE: This is a multicenter, dose-escalation study of irinotecan. Patients are stratified according to concurrent enzyme-inducing anti-epileptic drugs (EIAEDs) (e.g., phenytoin, phenobarbital, carbamazepine, or primidone) (yes vs no). In phase I of the study, patients receive oral temozolomide on days 1-5 and irinotecan IV over 90 minutes on days 1 and 14. Treatment continues every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients concurrently on EIAEDs undergo dose escalation of irinotecan. Cohorts of 3 to 6 patients receive escalating doses of irinotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity. In phase II of the study, patients receive the same treatment as in phase I at the MTD. Patients are followed every 2 months for 1 year, every 3 months for 1 year, every 4 months for 1 year, every 6 months until progression, and then every 4 months for survival. PROJECTED ACCRUAL: A total of 30 patients will be accrued for phase I within 10 months and 48 patients will be accrued for phase II within 6-8 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed supratentorial malignant primary glioma of one of the following subtypes: - Glioblastoma multiforme - Anaplastic astrocytoma - Anaplastic oligodendroglioma - Mixed malignant glioma - Original histology of low-grade glioma allowed if subsequent histological confirmation of malignant glioma - Measurable recurrent or residual primary disease by MRI - Lesions with clearly defined margins - Evidence of tumor recurrence or progression by MRI or CT scan - Confirmation of true progressive disease by PET or thallium scan, magnetic resonance spectroscopy, or surgical documentation after prior interstitial brachytherapy or stereotactic radiosurgery - No more than 3 relapses after prior chemotherapy/cytotoxic therapy (including polifeprosan 20 with carmustine implant) for phase I and no more than 2 relapses for phase II PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 60-100% Life expectancy: - Not specified Hematopoietic: - WBC at least 3,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin no greater than 1.5 mg/dL - SGOT no greater than 2 times upper limit of normal Renal: - Creatinine no greater than 1.5 mg/dL Cardiovascular: - No uncontrolled hypertension, unstable angina, or symptomatic congestive heart failure - No myocardial infarction within the past 6 months - No serious uncontrolled cardiac arrhythmia Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No mental incapacitation - HIV negative - No AIDS-related disease - No significant ongoing alcoholism or substance abuse - No severe nonmalignant systemic disease - No active infection - No other severe disease that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 1 week since prior interferon or thalidomide and recovered - No concurrent anticancer immunotherapy - No concurrent sargramostim (GM-CSF) - No concurrent prophylactic filgrastim (G-CSF) during first course of study therapy Chemotherapy: - See Disease Characteristics - Recovered from prior chemotherapy - At least 2 weeks since prior vincristine - At least 3 weeks since prior procarbazine - At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosourea) - Prior radiosensitizers allowed - No prior temozolomide or irinotecan - No other concurrent anticancer chemotherapy Endocrine therapy: - At least 1 week since prior tamoxifen and recovered - No concurrent anticancer hormonal therapy - Phase II: - Non-increasing dose of corticosteroids allowed Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy and recovered - No concurrent anticancer radiotherapy Surgery: - See Disease Characteristics - At least 1-3 weeks since prior surgical resection and recovered Other: - At least 1 week since prior noncytotoxic agents (e.g., isotretinoin) and recovered - Concurrent enzyme-inducing anti-epileptic drugs with or without steroids allowed - No concurrent valproic acid as a single agent - No concurrent medication that would preclude study (e.g., nonsteroidal immunosuppressive agents) - No other concurrent investigational drugs - No concurrent participation in other clinical study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
Wai-KwanYung, Study Chair, M.D. Anderson Cancer Center
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support *Recruiting*
Bethesda, Maryland, 20892-1182
United States
Recruiting Patient Recruitment 1-888-NCI-1937
Jonsson Comprehensive Cancer Center, UCLA *Recruiting*
Los Angeles, California, 90095
United States
Recruiting Timothy Cloughesy 310-825-5321
UCSF Comprehensive Cancer Center *Recruiting*
San Francisco, California, 94115
United States
Recruiting Michael Prados 415-353-9510
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Lisa DeAngelis 212-639-7123
University of Texas - MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030-4009
United States
Recruiting Wai-Kwan Yung 713-794-1285
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting Patrick Wen 617-632-2166
Hillman Cancer Center at University of Pittsburgh Cancer Institute *Recruiting*
Pittsburgh, Pennsylvania, 15232
United States
Recruiting Frank Lieberman 412-692-2600
University of Texas Health Science Center at San Antonio *Recruiting*
San Antonio, Texas, 78284-6220
United States
Recruiting John Kuhn 210-567-8355
University of Wisconsin Comprehensive Cancer Center *Recruiting*
Madison, Wisconsin, 53792
United States
Recruiting Minesh Mehta 608-263-8500
Additional Information:
Study ID Numbers: CDR0000068037; NABTC-9907,UCLA-0006095
Study Start Date:
Record last reviewed: September 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006025
Other Adult Glioblastoma Multiforme Studies:
1. PEG-Interferon alfa-2b With or Without Thalidomide in Treating Patients With Recurrent High-Grade Gliomas
2. Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
3. Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
4. EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
5. Carmustine in Treating Patients With Recurrent Malignant Glioma
Related Studies:
Other adult glioblastoma multiforme Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
|
|
|
|
|
|
|
|
